IPVS 2026 Special Interest Sessions Program | IPVS 2026

Click on each session title to access the agenda.

October 23, 2026

8:00 – 9:00 AM

Banqueting Hall

Female Genital Schistosomiasis (FGS): A New Frontier for Integration of Three WHO Prevention Priorities

8:00 – 9:00 AM

MC3 Hall

Sexual Partner Considerations When Delivering HPV-Positive Results

11:15 AM – 12:15 PM

Skalkotas Hall

Low-Risk HPV: Are Anogenital Warts and RRP Two Sides of the Same Coin?

11:15 AM – 12:15 PM

MC3 Hall

Can HPV with Extended Genotyping Plus AI Replace Cytology and Colposcopic Biopsy?

6:30 – 7:30 PM

MC3 Hall

Cell Biology of the Cervical Transformation Zone — Refining Our Understanding of Cervical Cancer Progression and Treatment Outcomes

6:30 – 7:30 PM

MC2 Hall

Sustaining HPV Vaccination Within Routine Immunization Systems: Evidence from Real-World Implementation

October 24, 2026

8:00 – 9:00 AM

MC3 Hall

Optimising Triage of HPV-Positive Women: Validation and Global Implementation of DNA Methylation Biomarkers for Cervical Cancer Screening

8:00 – 9:00 AM

MC2 Hall

Cervical Cancer Elimination Lab: Accelerating 90–70–90 Under Real-World Constraints

9:30 – 10:15 AM

MC2 Hall

Improving Access to Cervical Screening for Disabled People

10:15 – 11:00 AM

MC2 Hall

Where Are All the Anal Cancers? Insights into Global Variation in Anal Cancer Incidence

11:15 AM – 12:15 PM

Skalkotas Hall

Engineering the Next Generation of HPV Screening: From Nanobiosensors to Self-Sampling Platforms for Cervical Cancer Elimination

October 25, 2026

8:00 – 9:00 AM

Banqueting Hall

Reaching the Third Target: Can Thermal Ablation Close the Cervical Precancer Treatment Gap?

8:00 – 9:00 AM

MC2 Hall

Cervical Cancer Elimination in Low- and Middle-Income Countries: A New Paradigm — Integration, Not Imitation

9:15 – 10:15 AM

Banqueting Hall

HPV ‘Treatments’: Science, Regulation, and the Need for Evidence-Based Guidance

9:15 – 10:15 AM

MC2 Hall

Making Cervical Cancer Prevention Affordable: Domestic Financing Pathways for HPV Testing